This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Miltenyi Biotec
product type :
antibody
product name :
CD170 (Siglec-5) Antibody, anti-human, Vio® Bright B515, REAfinity™
catalog :
130-119-200
quantity :
30 tests in 60 µL
price :
189 USD
clonality :
monoclonal
host :
human
conjugate :
VioBright 515
clone name :
REA1077
reactivity :
human
application :
flow cytometry
citations: 2
Reference |
---|
Avril T, Freeman S, Attrill H, Clarke R, Crocker P. Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation. J Biol Chem. 2005;280:19843-51 pubmed
|
Erickson Miller C, Freeman S, Hopson C, D Alessio K, Fischer E, Kikly K, et al. Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes. Exp Hematol. 2003;31:382-8 pubmed
|
product information
MB Cataloge Number :
130-119-200
Catalog Number :
130-119-200
Product Name :
CD170 (Siglec-5) Antibody, anti-human, Vio® Bright B515, REAfinity™
Product Type :
Primary antibodies, Recombinant antibodies
Host Species :
recombinant human IgG1
Clonality :
monoclonal
Conjugation :
Vio Bright B515
Antigen Modification :
CD170 (Siglec-5)
Clone Name :
REA1077
Isotype :
REA Control Antibody (S), human IgG1
Size :
30 tests in 60 µL
US List Price :
189 USD
Product Description :
Identification and enumeration of CD170 (Siglec-5)+ cells by flow cytometry
CrossReactivity :
chimpanzee (Pan troglodytes), bonobo (Pan paniscus)
ALTnames :
CD33L2, OB-BP2, OBBP2, Siglec-5
Specificity :
human, non-human primate
Concentration :
1:50
Uses :
For research use only
Application Summary :
Flow cytometry
Storage :
Store protected from light at 2–8 °C. Do not freeze.
company information
Miltenyi Biotec
Friedrich-Ebert-Strae 68
51429 Bergisch Gladbach
51429 Bergisch Gladbach
macs@miltenyibiotec.com
https://www.miltenyibiotec.com1 800 FOR MACS
headquarters: Germany
questions and comments